{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=47&state=Georgia",
    "query": {
      "state": "Georgia",
      "city": "Atlanta",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 13075,
    "total_pages": 1308,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=48&state=Georgia&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Atlanta&page=46&state=Georgia&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T18:18:01.140Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05877963",
      "title": "Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 800,
      "start_date": "2023-06-13",
      "completion_date": "2027-01-21",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-15T18:18:01.140Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05877963"
    },
    {
      "nct_id": "NCT03488693",
      "title": "Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "No Radiation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Canadian Cancer Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "35 Years and older · Female only"
      },
      "enrollment_count": 2138,
      "start_date": "2018-10-16",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-15T18:18:01.140Z",
      "location_count": 451,
      "location_summary": "Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03488693"
    },
    {
      "nct_id": "NCT05581004",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumors",
        "NSCLC",
        "HNSCC",
        "Melanoma",
        "TNBC",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Urothelial Carcinoma",
        "Clear Cell RCC",
        "HCC"
      ],
      "interventions": [
        {
          "name": "Enzelkitug",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2022-10-20",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-15T18:18:01.140Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05581004"
    },
    {
      "nct_id": "NCT00098748",
      "title": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Optimized Background Therapy (OBT)",
          "type": "DRUG"
        },
        {
          "name": "maraviroc (UK-427,857)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2004-11",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2010-12-07",
      "last_synced_at": "2026-11-15T18:18:01.140Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098748"
    },
    {
      "nct_id": "NCT00329264",
      "title": "Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Quetiapine fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 876,
      "start_date": "2006-04",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2009-03-25",
      "last_synced_at": "2026-11-15T18:18:01.140Z",
      "location_count": 58,
      "location_summary": "Springdale, Arizona • Little Rock, Arkansas • Encino, California + 55 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00329264"
    },
    {
      "nct_id": "NCT06770998",
      "title": "A Study of a Novel EEG Neurofeedback System for PTSD Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress Disorders, Post-Traumatic"
      ],
      "interventions": [
        {
          "name": "EEG-neurofeedback training",
          "type": "DEVICE"
        },
        {
          "name": "Sham training",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Foundation for Atlanta Veterans Education and Research, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 250,
      "start_date": "2025-05-14",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-11-15T18:18:01.140Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06770998"
    },
    {
      "nct_id": "NCT01581593",
      "title": "Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency",
        "Agammaglobulinemia",
        "Hypogammaglobulinemia",
        "Antibody Deficiency"
      ],
      "interventions": [
        {
          "name": "Kedrion IVIG 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kedrion S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "2 Years to 70 Years"
      },
      "enrollment_count": 45,
      "start_date": "2012-11-12",
      "completion_date": "2014-08-27",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-11-15T18:18:01.140Z",
      "location_count": 12,
      "location_summary": "Little Rock, Arkansas • North Palm Beach, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01581593"
    },
    {
      "nct_id": "NCT05003804",
      "title": "Allergic Disease Onset Prevention Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Type 1 Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "STMC-103H",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Siolta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "14 Days",
        "sex": "ALL",
        "summary": "0 Days to 14 Days"
      },
      "enrollment_count": 283,
      "start_date": "2021-09-01",
      "completion_date": "2025-10-21",
      "has_results": false,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-11-15T18:18:01.140Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05003804"
    },
    {
      "nct_id": "NCT02055638",
      "title": "Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Intermittent Explosive Disorder"
      ],
      "interventions": [
        {
          "name": "SRX246",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Azevan Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 97,
      "start_date": "2014-05",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-11-15T18:18:01.140Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • O'Fallon, Missouri + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "O'Fallon",
          "state": "Missouri"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02055638"
    },
    {
      "nct_id": "NCT04158648",
      "title": "A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor",
        "Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor",
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 73,
      "start_date": "2020-02-10",
      "completion_date": "2025-12-19",
      "has_results": true,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-11-15T18:18:01.140Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04158648"
    }
  ]
}